Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies.
Spyre Therapeutics has raised $403.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
Spyre Therapeutics's investors include Cormorant Asset Management, Adage Capital Management, Perceptive Advisors, RTW Investments, Farallon Capital Management.
Spyre Therapeutics is headquartered in Sunrise, United States.
Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies.
Spyre Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Spyre Therapeutics — Funding & Investors." VCBacked, April 14, 2026, https://www.vcbacked.co/company/spyre-therapeutics. Accessed July 19, 2026.
VCBacked. (2026). Spyre Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/spyre-therapeutics
{{cite web |title=Spyre Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/spyre-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated